• Oruka Therapeutics director Carl Dambkowski sold 35,000 common shares on June 11-12.
• Sales priced at about USD 70.13 per share on June 11, about USD 70.11 on June 12.
• Holdings fell to 38,743 common shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000907654-26-000054), on June 12, 2026, and is solely responsible for the information contained therein.